| anistreplase versus placebo | |||
| UNASEM, 1992 | anistreplase IV 30 UI over 5 minutes versus placebo | Patients without a previous myocardial infarction, with a typical history of unstable angina and ECG abnormalities indicative of ischemia | double blind Follow-up duration: hospital stay, 1y Europe |
| apixaban versus placebo | |||
| APPRAISE 2, 2011 NCT00831441 | apixaban 5mg twice daily versus placebo | patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events | double blind Follow-up duration: 8 months 39 countries |
| APPRAISE-1 (10mg od), 2009 NCT00313300 | apixaban 10 mg once daily versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| APPRAISE-1 (2.5 mg bid), 2009 NCT00313300 | Apixaban 2.5mg twice daily
versus placebo | patients with a recent ST-elevation or non–ST-elevation acute coronary syndrome(<7 days) | double blind Follow-up duration: 6 months Europe, Middle East, North America |
| Argatroban versus heparin | |||
| ARGAMI-2, 1998 | Argatroban 60–20 mg/kg bolus; 2–4 µg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion | AMI | Follow-up duration: 30 days |
| ASA high dose versus ASA low dose | |||
| CURRENT - OASIS 7 (ASA), 2010 NCT00335452 | High-dose aspirin
versus Low-dose aspirin | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | open Follow-up duration: 30 days |
| aspirin versus control | |||
| Huddinge, 1988 | aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month versus no aspirin | patients with acute myocardial infarction | open Follow-up duration: 30d (12m) |
| ATACS-pilot, 1990 | Aspirin 80mg/d (Heparin + Warfarin) versus full-dose heparin followed by warfarin | acute coronary syndromes | Follow-up duration: 3m |
| Frankfurt, 1976 | A1320 + D300, A1320 versus | Follow-up duration: 14d | |
| aspirin versus placebo | |||
| VA-main, 1983 | Aspirin 324mg/d versus placebo | men with unstable angina | double blind Follow-up duration: 3m |
| ISIS-pilot, 1987 | aspirin (325 mg on alternate days for 28 days) versus placebo | suspected acute myocardial infarction | double blind Follow-up duration: 1m |
| ISIS-2, 1988 | 160 mg/day enteric-coated aspirin for one month versus placebo | suspected acute myocardial up to 24h | double blind Follow-up duration: 35d |
| VA-pilot, 0 | Aspirin 324 mg/d versus | Follow-up duration: 3m | |
| RISC, 1990 | Aspirin 75mg/d versus placebo | men with unstable coronary artery disease (unstable angina or non-Q wave myocardial infarction | double blind Follow-up duration: 12m Sweden |
| Canadian (Aspirin vs PBO), 1985 | Aspirin 1300mg/d versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| ALDUSA-pilot, 0 | Aspirin 325mg/d, Aspirin 40mg/d versus | Follow-up duration: 12m | |
| Dutch-aspirin, 1990 | aspirin (100 mg/day) for 3 months versus placebo | patients with first anterior wall AMI | double blind Follow-up duration: 3m |
| Théroux, 1988 | Aspirin 325 mg twice daily versus placebo | acute unstable angina | double blind Follow-up duration: 6d (3m) |
| APRICOT, 1993 | 325 mg aspirin daily with discontinuation of heparin versus placebo | Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hours | double blind Follow-up duration: 3m The Netherlands |
| aspirin + dipyridamol versus placebo | |||
| Prandoni, 1991 | Aspirin 50mg/d + Dipyridamol 400mg/d versus placebo | patients with acute unstable angina | double blind Follow-up duration: 12m |
| aspirin + sulfinpyrazone versus placebo | |||
| Canadian (Aspirin + sulfinpyrazone), 1985 | Aspirin 1300mg/d + sulfinpyrazone 800mg/d versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| atopaxar versus placebo | |||
| LANCELOT ACS, | 400-mg loading dose of atopaxar followed by a daily dose of 50 mg, 100 mg, or 200 mg for 12 weeks versus placebo | unstable-angina or non-STEMI patients | |
| J-LANCELOT, 2010 | atopaxar at a loading dose of 400 mg followed by 50 mg per day, 100 mg per day, or 200 mg per day for 12 weeks versus atopaxar at a loading dose of 400 mg followed by placebo | patients with acute coronary syndrome (unstable angina and NSTEMI) | Japan |
| atorvastatin versus placebo | |||
| MIRACL, 2001 | Atorvastatin, 80 mg (early initiation) versus Placebo | unstable angina or non–Q-wave acute MI | Double blind Follow-up duration: 1 and 4 months Europe, North America, South Africa, and Australasia |
| atorvastatin versus pravastatin | |||
| PROVE IT - TIMI 22, 2004 | 80 mg of atorvastatin daily (intensive therapy). versus 40 mg of pravastatin daily (standard therapy) | patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days | double blind Follow-up duration: 24 mo (18-36 mo) UK, US, AUstralia, Italy, France, Germany, Spain, Canada |
| atorvastatin versus usual care | |||
| Colivicchi, 2002 | Atorvastatin, 80 mg daily early initiation versus Usual care | unstable angina pectoris or non-Q-wave myocardial infarction | open Follow-up duration: 1, 3, and 6 months Italy |
| ESTABLISH, 2004 | Atorvastatin, 20 mg early initiation versus Usual care | patients with ACS undergoing emergency coronary angiography and percutaneous coronary intervention | open Follow-up duration: 1, 4, and 6 months Japan |
| bivalirudin versus eptifibatide + heparin | |||
| PROTECT-TIMI 30, 2006 NCT00250471 | bivalirudin alone versus eptifibatide plus either unfractionated heparin or enoxaparin | non ST elevation ACS patients undergoing PCI | open Follow-up duration: hospital stay International |
| bivalirudin versus heparin | |||
| HERO, 1997 | Bivalirudin 0.125–0.250 mg/kg bolus; 0.125–0.500 mg /kg/min infusion for 72h versus UFH 5000 IU bolus; 1000–1200 IU/h infusion | AMI (patients presenting within 12 hours with ST-segment elevation) | double blind Follow-up duration: 35 days |
| BAT (Bittl), 1995 | Bivalirudin 1.0 mg/kg bolus; 2.5 mg /kg/h for 4 h, then 0.2 mg /kg/h infusion for 24h versus UFH 175 IU/kg bolus; 15 IU mg /kg/h infusion | patients undergoing angioplasty for unstable or postinfarction angina | double blind Follow-up duration: 6 months North America and Europe |
| bivalirudin versus heparin + GP2b3a inhibitors | |||
| ACUITY (biva alone vs hep+aGP2b3a), 2006 NCT00093158 | bivalirudin alone versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. | double blind Follow-up duration: 30 days 17 countries worldwide |
| ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 | bivalirudin alone versus heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors | patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography (sub group). | open Follow-up duration: 30 days |
| bivalirudin + GP2b3a inhibitors versus heparin + GP2b3a inhibitors | |||
| ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 NCT00093158 | bivalirudin plus a glycoprotein IIb/IIIa inhibitor
versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | in patients with moderate- or high-risk acute coronary syndromes who were undergoing an early invasive strategy. | double blind Follow-up duration: 30 days 17 countries worldwide |
| ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 | bivalirudin +
versus heparin (either unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors | patients with moderate and high-risk acute coronary syndromes undergoing percutaneous coronary intervention after angiography. | open Follow-up duration: 30 days |
| cangrelor up front versus clopidogrel up front | |||
| CHAMPION-PCI, 2009 NCT00305162 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) versus clopidogrel up front (clopidogrel followed by placebo) | high risk patients requiring PCI | double blind Follow-up duration: 48 h 14 countries |
| cangrelor up front versus delayed clopidogrel | |||
| CHAMPION-PLATFORM, 2009 NCT00385138 | cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel) versus delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) | patients with acute coronary syndrome undergoing percutaneous coronary intervention | double blind Follow-up duration: 48 h 18 countries |
| clopidogrel versus placebo | |||
| CURE (PCI sub study), 2001 | pretreatment with clopidogrel -+aspirin 75–325 mg) versus placebo (+ aspirin 75–325 mg) | patients with non-ST-elevation acute coronary syndrome undergoing PCI | double blind |
| COMMIT, 2005 NCT00222573 | clopidogrel 75 mg daily versus placebo | patients admitted to hospital within 24 h of suspected acute MI onset | double-blind Follow-up duration: until discharge or up to 4 wee |
| CLARITY-TIMI 28, 2005 | clopidogrel (300-mg loading dose, followed by 75 mg once daily)
versus placebo | patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction | double blind Follow-up duration: 30 days |
| clopidogrel + aspirin versus aspirin | |||
| CURE, 2001 | clopidogrel 300 mg immediately, followed by 75 mg once daily + aspirin for 3 to 12 months versus aspirin (+placebo) | acute coronary syndromes without ST-segment elevation within 24 hours after the onset of symptoms | double blind Follow-up duration: NA (median <9 months) 28 countries |
| clopidogrel high-dose regimen versus clopidogrel standard-dose | |||
| CURRENT OASIS 7 (clopidogrel), 2010 NCT00335452 | Double-dose clopidogrel versus Standard-dose clopidogrel | ACS patients referred for an invasive strategy (scheduled for percutaneous coronary intervention no more than 72 hours after randomization) | open Follow-up duration: 30 days |
| coumadin versus aspirin | |||
| ASPECT-2 (coumadin vs aspirin), 2002 | coumadin (phenprocoumon or acenocoumarol) target INR 3-4)
versus aspirin 80mg daily | UA, AMI | open Follow-up duration: 1 year (range 0-26 months) the Netherlands |
| coumadin versus control (on top of aspirin) | |||
| ASPECT-2 (coumadin+asp vs asp), 2002 | coumadin(INR mean 2.4) +aspirin versus aspirin | UA, AMI | open Follow-up duration: 1 year the Netherlands |
| dabigatran versus placebo | |||
| REDEEM, 2009 NCT00621855 | dabigatran 4 dosages (50mg twice daily, 75mg twice daily, 110mg twice daily, 150mg twice daily) versus placebo | patients with recent acute coronary syndromes (ST- or non-ST-elevation myocardical infarction) | double blind Follow-up duration: 6 months |
| dalteparin versus placebo (on top of aspirin) | |||
| FRIC prolonged treatment phase (LWMH vs PBO), 1997 | dalteparin SC 120 i.u./kg twice-daily for 6 days followed by dalteparin 7500UI daily up to day 45 (+aspirin) versus unfractionated heparin dose-adjusted intravenous infusion (for at least 48h) then by subcutaneous injection up to day 6 (then placebo) (+aspirin) | Patients with unstable angina or non-Q-wave myocardial infarction | double blind Follow-up duration: 45 days |
| FRISC (long term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin versus matched placebo + aspirin | patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours | double blind Follow-up duration: 40 days Sweden |
| FRISC (short term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin
versus matched placebo + aspirin | patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours | double blind Follow-up duration: 6 days Sweden |
| dalteparin versus UFH (on top of aspirin) | |||
| FRIC (acute phase LMWH vs UFH), 1997 | twice-daily weight-adjusted subcutaneous injections of dalteparin (120 i.u./kg) (+aspirin)
versus dose-adjusted intravenous infusion of unfractionated heparin (+aspirin) | Patients with unstable angina or non-Q-wave myocardial infarction | open Follow-up duration: 6 days |
| dazoxiben versus control | |||
| Jones, 1987 | DZ versus | Follow-up duration: 1m | |
| diltiazem versus placebo | |||
| Göbel (Dutch study), 1995 | diltiazem intravenously versus glyceryl trinitrate intravenously | patients with unstable angina | double blind Follow-up duration: ND |
| DRS, 1986 | diltiazem 90 mg every six hours up to 14 days versus placebo | patients with non-Q-wave myocardial infarct, 24 to 72 hours after the onset of infarction | double blind Follow-up duration: ND |
| early intervention versus early strategy | |||
| ISAR-COOL, 2003 | Prolonged (3 to 5 days) antithrombotic
pretreatment (“Cooling-Off” strategy)
before intervention versus early intervention after pretreatment for less than 6 hours | patients with symptoms of unstable angina plus either ST-segment depression or elevation of cardiac troponin T levels | open Follow-up duration: 1 mo Germany |
| early invasive management versus delayed invasive strategy | |||
| TIMACS, 2009 NCT00552513 | early invasive management: angiography within 24 hours followed by PCI or CABG as appropriate versus delayed invasive strategy: angiography after 36 hours followed by PCI or CABG as appropriate | patients with unstable angina or non-ST-segment-elevation MI (NSTEMI) | open Follow-up duration: 6 months 30 countries |
| Efegatran versus heparin | |||
| Klootwijk, 1999 | Efegatran 0.1–0.3 mg/kg bolus; 0.105–1.200 mg /kg/h infusion for 48h versus UFH 5000 IU bolus; 1000 IU/h infusion | patients with unstable angina | open Follow-up duration: 30 days |
| elinogrel versus placebo | |||
| ERASE-MI, 2009 | elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus versus placebo | STEMI patients | double blind Follow-up duration: 30-37 days |
| enoxaparin versus tinzaparin | |||
| EVET, 2005 | enoxaparin, 100 IU/kg subcutaneously twice daily +aspirin for 7 days versus tinzaparin, 175 IU/kg subcutaneously once daily +aspirin for 7 days | patients with non-ST-segment elevation acute coronary syndromes | open Follow-up duration: 30 days |
| enoxaparin versus UFH (on top of aspirin) | |||
| ESSENCE, 1997 | enoxaparin 1mg/kg, twice daily during 48h-8days versus continuous intravenous unfractionated heparin | patients with angina at rest or non–Q-wave myocardial infarction | Double blind Follow-up duration: 14 days (30 days) United states, Canada, South America, Europe |
| INTERACT, 2006 | enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) versus intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin) | high-risk patients with ACS receiving aspirin and eptifibatide | open Follow-up duration: 30 days (2.5y) Canada |
| SYNERGY, 2005 NCT00043784 | Enoxaparin 1 mg/kg twice daily versus unfractionated heparin | high-risk patients with acute coronary syndromes | open Follow-up duration: 30 days 12 countries |
| TIMI 11 B (long term), 1998 | enoxaprin during both the acute phase (IV) and outpatient phase (SC)
versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction | double blind Follow-up duration: 43 days North America, South America, |
| TIMI 11 B (short term), 1998 | enoxaprin during both the acute phase and outpatient phase versus intravenous UFH for >=3 days (followed by subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction | double blind Follow-up duration: 8 days (43 days) North America, South America, |
| enoxaparin versus unfractionated heparin | |||
| RESCUE, NCT00077818 | Enoxaparin versus unfractionated heparin | patients diagnosed with acute coronary syndrome in the emergency department | open Follow-up duration: 30 days |
| Entonox versus placebo | |||
| Kerr, 1975 | nitrous oxide 50%/oxygen 50% ('Entonox" analgesic apparatus) versus placebo | double-blind | |
| error versus control | |||
| Dekleva, 2004 | versus | ||
| ezetimibe versus placebo (on top statins) | |||
| IMPROVE-IT, 2014 NCT00202878 | 10 mg/day of ezetimibe and 40 mg/day of simvastatin versus simvastatin 40 mg/day | subjects with stabilized high-risk acute coronary syndrome | double blind Follow-up duration: 5.68 years 39 countries |
| flurbiprofen versus placebo | |||
| French, 1993 | flurbiprofen 50 mg twice daily versus placebo | patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms | double blind Follow-up duration: 6m |
| fluvastatin versus placebo | |||
| LIPS (sub groups), 2002 | Fluvastatin, 80 mg versus Placebo | patients with unstable angina and successful first percutaneous coronary intervention | double blind Follow-up duration: 1, 4, and 6 months Europe, Canada, and Brazil |
| FLORIDA, 2002 | Fluvastatin, 80 mg (early initiation) versus Placebo | patients with an AMI and total cholesterol of <6.5 mmol.l | double blind Follow-up duration: 1, 4, and 6 months The Netherlands |
| fondaparinux versus enoxaparin | |||
| OASIS 5, 2006 NCT00139815 | fondaparinux 2.5 mg daily until hospital discharge or for up
to eight days versus enoxaparin 1 mg per kilogram of body weight twice daily for two to eight days or until the patient was in clinically stable condition | patients with acute coronary syndromes | double blind Follow-up duration: 9 days (180 days) 41 countires |
| PENTUA, 2004 | Four doses fondaparinux (2.5, 4, 8, or 12 mg once daily) for three to seven days versus enoxaparin (1 mg/kg twice daily) for three to seven days | patients with ACS without persistent ST-segment elevation | Follow-up duration: 9 days |
| GR3219B versus control | |||
| GRAND, 1987 | GRB versus | Follow-up duration: 1m | |
| Hirudin versus heparin | |||
| HIT-4, 1999 | Hirudin 0.2 mg/kg bolus; 0.5 mg/kg twice daily 0.1 mg/kg 0.1 mg /kg/h infusion for 5-7 days versus Placebo bolus, UFH 12 500 IU twice daily | patients with AMI <=6 h were treated with aspirin and streptokinase | double blind Follow-up duration: 30 days |
| OASIS, 1997 | low-dose hirudin (0.2 mg/kg bolus+0.10 mg/kg/h infusion) or medium-dose hirudin (0.4 mg/kg bolus+0.15 mg/kg/h infusion) for 72h versus heparin 5000 IU bolus+1000 to 1200 U/h | patients with unstable angina or suspected acute MI without ST-segment elevation | open Follow-up duration: 7 days |
| TIMI 9B, 1996 | Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 96h versus UFH 5000 IU bolus; 1000 IU/h infusion | Unstable angina or AMI | open Follow-up duration: 30 days |
| GUSTO IIB, 1996 | Hirudin 0.1 mg/kg bolus; 0.1 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 1000 IU/h infusion for 72H | patients with acute coronary syndromes | open Follow-up duration: 30days (1 year) |
| OASIS pilot, 1997 | Hirudin 0.2–0.4 mg/kg bolus; 0.10–0.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 1000–1200 IU/h infusion | patients with unstable angina or suspected acute MI without ST-segment elevation | open Follow-up duration: 6 months |
| OASIS 2, 1999 | Hirudin 0.4 mg/kg bolus; 0.15 mg /kg/h infusion for 72h versus UFH 5000 IU bolus; 15 IU /kg/h infusion | patients with unstable angina or suspected acute myocardial infarction without ST elevation | double blind Follow-up duration: 7 days (6 months) |
| HELVETICA (Serruys), 1995 | Hirudin 40 mg intravenous bolus; 0.2 mg /kg/h infusion for 24 h, then 40 mg or placebo twice daily for 72h versus UFH 10 000 IU bolus; 15 IU /kg/h infusion for 24 h, then placebo twice daily | patients with unstable angina who were scheduled for angioplasty | double blind Follow-up duration: 6 months |
| hyperbaric oxygen versus control | |||
| Sharifi, 2004 | hyperbaric oxygen therapy versus | after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris | |
| Swift, 1992 | hyperbaric oxygen versus | patients within 1 week of acute myocardial infarction | |
| Thurston, 1973 | hyperbaric oxygen versus | acute myocardial infarction | |
| Hot MI, 1997 | Hyperbaric oxygen versus | Patients with an acute myocardial infarction who received recombinant tissue plasminogen activator | |
| Hyperbaric oxygen versus control | |||
| HOT MI pilot, 1997 | Hyperbaric oxygen versus | Patients with an acute myocardial infarction (AMI) who received recombinant tissue plasminogen activator | |
| immediate invasive management versus delayed invasive strategy | |||
| ABOARD, 2009 NCT00442949 | immediate catheterization and revascularization
versus catheterization and revascularization on the next working day (between 8 and 60 hours after enrollment) | patient with non ST-elevation acute coronary syndrome | open Follow-up duration: 1 month France |
| OPTIMA, 2009 ISRCTN80874637 | immediate angioplasty under triple
antiplatelet therapy protection versus deferred angioplasty | patients with non-ST-segment elevation acute coronary syndromes eligible for percutaneous coronary intervention | open Follow-up duration: 30 days The Netherland, England |
| Inogatran versus heparin | |||
| TRIM, 1997 | Inogatran 0.1–5.5 mg bolus; 2.0–10.0 mg/h infusion for 72h versus UFH 5000 IU bolus; 1200 IU/h infusion | patients with suspected unstable angina, or non-Q wave myocardial infarction | double blind Follow-up duration: 30 days |
| intracoronary urokinase versus placebo | |||
| TAUSA, 1994 | intracoronary urokinase 250000 UI or 500000 UI versus placebo | ischemic rest pain with or without a recent (< 1 month) infarction | double blind Follow-up duration: hospital stay USA |
| LMWH versus placebo (on top of aspirin) | |||
| Gurfinkel (LMWH+asp vs asp), 1995 | aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin (200 mg/day | patients with unstable angina | single blind Follow-up duration: 5-7 days |
| LMWH versus UFH (on top of aspirin) | |||
| Gurfinkel (LMWH+asp vs UFH+asp), 1995 | aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin plus regular heparin (400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time | patients with unstable angina | single blind Follow-up duration: 5-7 days |
| misc. versus control | |||
| Gent-AMI, 1968 | D400 versus | Follow-up duration: 28d | |
| Johannessen, 1989 | A150 + D225 versus | Follow-up duration: 14d | |
| nadroparin versus UFH (on top of aspirin) | |||
| FRAXIS (14 days), 1998 | nadroparin for 14 days
versus unfractionated heparin for 14 days | unstable angina or non-Q wave myocardial infraction | double blind Follow-up duration: 14 days 17 countries |
| FRAXIS (6days), 1998 | nadroparin for 6 days (+aspirin) versus unfractionated heparin for 6 days (+aspirin) | unstable angina or non-Q wave myocardial infraction | Double blind Follow-up duration: 14 days 17 countries |
| nifedipine versus metoprolol | |||
| HINT (nifedipine vs metoprolol), 1988 | nifedipine versus metoprolol | patients with unstable angina not pretreated with a beta-blocker and of nifedipine | ND Follow-up duration: ND |
| otamixaban versus unfractionated heparin | |||
| SEPIA-ACS1 TIMI 42, 2009 NCT00317395 | otamixaban 5 doses (0·08 mg/kg bolus followed by 0.035, 0.070, 0.105, 0.140, 0.175 mg/kg/h) versus Heparin+eptifibatide | patients with non-ST-elevation acute coronary syndromes | double blind Follow-up duration: 7 days 36 countries |
| oxygen therapy versus control | |||
| Rawles, 1976 | oxygen administered by MC mask throughout the first 24 hours versus air | myocardial infarction | |
| Ukholkina, 2005 | oxygenotherapy versus | patients with acute myocardial infarction | |
| Wilson, 1997 | oxygen therapy versus control | patients presenting within 24 hours of onset of myocardial infarction | |
| pitavastatin versus atorvastatin | |||
| JAPAN ACS, 2009 NCT00242944 | pitavastatin 4 mg daily versus atorvastatin 20mg daily | patients with acute coronary syndrome undergoing IVUS-guided percutaneous coronary intervention | open Follow-up duration: 8-12 months Japan |
| prasugrel versus clopidogrel | |||
| TRILOGY ACS (overall population), 2012 NCT00699998 | prasugrel 10 mg daily versus clopidogrel 75 mg daily | patients with acute coronary syndromes selected for a final treatment strategy of medical management without revascularization within 10 days after the index event | double-blind Follow-up duration: 17 months (median) 52 countries |
| TRITON-TIMI 38, 2007 NCT00097591 | prasugrel 60-mg loading dose
and 10-mg daily maintenance dose, for 6 to 15 months versus clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose) for 6 to 15 months | patients with moderate-to-high-risk acute coronary syndromes (UA, NSTEMI,STEMI) with scheduled percutaneous coronary intervention | double blind 30 countries |
| JUMBO-TIMI 26, 2005 | Prasugrel 3 doses versus clopidogrel 300mg loading dose followed by 75 mg daily) | patients undergoing elective or urgent percutaneous coronary intervention | double blind Follow-up duration: 30 days |
| pravastatin versus placebo | |||
| LAMIL, 1997 | Pravastatin, 10-20 mg (starting at D3) versus Placebo | patients suffering an acute myocardial infarction | double blind Follow-up duration: 1 and 3 months Belgium |
| RECIFE, 1999 | Pravastatin, 40 mg versus Placebo | Patients with acute myocardial infarction or unstable angina and total cholesterol levels at admission >=5.2 mmol/L or LDL >=3.4 mmol/L | double blind Follow-up duration: 1.5 months Canada |
| PAIS, 2001 | Pravastatin, 40 mg (initiated within 48 hours of hospital admission) versus Placebo | patients with acute coronary syndromes | double blind Follow-up duration: 1 and 3 months The Netherlands |
| PACT, 2004 | Pravastatin, 20-40 mg within 24 hours of the onset of symptoms in versus Placebo | patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction within 24 hours of the onset of symptoms | double blind Follow-up duration: 1 months Australia |
| pravastatin versus usual care | |||
| L-CAD, 2000 | Pravastatin, 20-40 mg (strating on average at D6) versus Usual care | patients with acute coronary syndrome | open Follow-up duration: 1, 4, and 6 months Germany |
| PTT, 2002 | Pravastatin, 40 mg versus Usual care | patients who underwent coronary balloon angioplasty of the infarct-related artery during the first month of acute myocardial infarction | open Follow-up duration: 1 and 6 months Turkey |
| ranolazine versus placebo | |||
| MERLIN TIMI 36, 2007 NCT00099788 | ranolazine 1000 mg twice daily for the duration of the trial (intitialy 200 mg intravenously for 1 hour, followed by an 80 mg/h intravenous infusion) versus placebo | Hospitalized with NSTE-ACS; ischemic symptoms at rest within 48 hours; and at least one indicator of moderate to high risk, defined as elevated troponin or creatine kinase-myocardial band, ST-depression >0.1 mV, diabetes, or TIMI risk score for unstable angina/NSTEMI >=3 | Double blind Follow-up duration: median 11.4 months 17 countries |
| rivaroxaban 2.5mg versus placebo | |||
| ATLAS ACS-TIMI 46 (2.5mg), 2009 NCT00402597 | rivaroxaban 2.5 mg twice daily
versus placebo | recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730) | double blind Follow-up duration: 6 months 27 countries |
| ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 NCT00809965 | rivaroxaban 2.5 mg twice daily in addition to standard care versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| rivaroxaban 5mg versus placebo | |||
| ATLAS ACS-TIMI 46 (5mg), 2009 NCT00402597 | rivaroxaban 5 mg twice daily
versus placebo | recent ACS patients treated with aspirin alone (n=761) or aspirin plus clopidogrel (n=2730) | double blind Follow-up duration: 6 months 27 countries |
| ATLAS ACS 2 - TIMI 51 (5mg), 2011 NCT00809965 | rivaroxaban 5 mg twice daily in addition to standard care
versus placebo | patients with a recent ACS | double blind Follow-up duration: 13 months 44 countries |
| routine invasive strategy versus concervative strategy | |||
| ICTUS, 2007 ISRCTN82153174 | early invasive strategy versus selective invasive treatment strategy | patients with non–ST-segment elevation acutec oronary syndrome and elevated cardiac troponin T | open Follow-up duration: 12 mo (4y) Netherlands |
| FRISC 2, 1999 | early invasive treatment strategy: angiography within 7 days aiming for revascularisation versus non-invasive treatment strategy: angiography only in patients with refractory or recurrent symptoms despite maximum medical treatment or severe ischemia during exercise test before discharge | patients with non–ST-segment elevation acutecoronary syndrome | Open Follow-up duration: 24 mo Scandinavia |
| NQWMI (Eisenberg), 2005 | Invasive (angiography at days 2 to 5) versus Noninvasive (stress testing at day 2 to 5) | patients with non–Q-wave myocardial infarction | open Follow-up duration: 12 months Canada |
| RITA 3, 2002 ISRCTN07752711r | routine angiography followed by
revascularisationage/pj versus conservative strategy (ischaemia-driven or symptom-driven angiography€S | patients with non–ST-segment elevation acutecoronary syndrome | open Follow-up duration: 24 mo (60 mo) UK |
| TACTICS-TIMI 18, 2001 | early invasive management strategy versus conservative management strategy | patients with non–ST-segment elevation acute coronary syndrome | open Follow-up duration: 6 mo 9 countries |
| TRUCS, 2000 | invasive strategy versus conservative strategy | patients with non–ST-segment elevation acute coronary syndrome in geographically isolated hospitals without cardiac surgical facilities | Follow-up duration: 12 mo Greece |
| VINO, 2002 | first day angiography / angioplasty strategy versus early conservative therapy | patients with non–ST-segment elevation acute coronary syndrome | open Follow-up duration: 6 mo Czech Republic |
| TACTICS-TIMI 18 elderly (sub group), 2001 | early invasive management strategy
versus conservative management strategy | patients 65 years of age and older with unstable angina and non–STsegment elevation myocardial infarction | open Follow-up duration: 6 mo 9 countries |
| routine invasive strategy - noncomptemporary versus concervative strategy | |||
| MATE, 1998 | early triage angiography and subsequent
therapies based on the angiogram versus conventional medical therapy | acute MI ineligible for thrombolytic therapy within 24 h of symptoms | open Follow-up duration: 21 mo US |
| TIMI 3B (PTCA), 1994 | Early invasive strategy: systematic angiography (18-48h after randomisation) and revascularisation (PTCA or CABG) versus Early elective strategy: angiography and revascularisation only in case of ischemic recurrence (see paper) | patient with unstable angina or non Q wave MI within 24hrs of onset | Open Follow-up duration: 12 mo USA & Canada |
| VANQWISH, 1998 | invasive management versus conservative management: medical therapy with subsequent invasive management if indicated by the development of spontaneous or indicible ischemia within 24-72 hours | Patients with Non–Q-wave myocardial infarction | Open Follow-up duration: 23 mo US |
| simvastatin versus placebo | |||
| A to Z, 2004 | Simvastatin, 40-80 mg early initiation versus Placebo | patient with an acute coronary syndrome (ACS) | Double aveugle Follow-up duration: 4 months 41 countries |
| sulfinpyrazone versus control | |||
| Dutch sulphinpyrazone, 1986 | S (W) versus | Follow-up duration: 21d | |
| sulfinpyrazone versus placebo | |||
| Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone 800mg/d
versus placebo | patients with unstable angina | double blind Follow-up duration: 18m |
| Wilcox, 1980 | Sulphinpyrazone 200 mg four times daily versus placebo | patients with acute myocardial infarction | Follow-up duration: 10d |
| Louvain sulphinpyrazone, 1983 | sulphinpyrazone, 4 x 200 mg daily for 7 days versus placebo | recent myocardial infarction | double blind Follow-up duration: 7d |
| supersaturated oxygen versus control | |||
| AMIHOT II , 2000 NCT00175058 | 90-minute intracoronary supersaturated oxygen (SSO(2)) infusion in the left anterior descending artery infarct territory versus control | patients with anterior ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention within 6 hours of symptom onset | |
| AMIHOT, 2007 | hyperoxemic reperfusion for 90 min using intracoronary aqueous oxygen versus normoxemic blood autoreperfusion | patients with acute anterior or large inferior AMI undergoing primary or rescue PCI (<24 h from symptom onset) and successful PCI | |
| surgery versus medical treatment | |||
| VA cooperative, 1987 | coronary-artery bypass surgery plus medical therapy versus medical therapy alone | men with unstable angina pectoris | open Follow-up duration: 2 years (5,10 years) US |
| t-PA versus placebo | |||
| Nicklas, 1989 | rt-PA, 150 mg/8 h versus placebo | patients with rest angina, angiographically documented coronary artery disease and pacing-induced ischemia | Double blind USA |
| Gold, 1987 | intravenous recombinant human tissue-type plasminogen activator (rt-PA). versus placebo | chest pain at rest with transient ST segment deviation of at least 1 mm | |
| Williams, 1990 | tissue-type plasminogen activator (rt-PA) (0.75 mg/kg over 1 hour or (0.75 mg/kg over 1 hour; total dose, 100 mg over 6 hours) versus placebo | rest angina and angiographic evidence of coronary stenosis | double blind USA |
| Freeman, 1992 | tissue-type plasminogen activator (t-PA) (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours) versus placebo | patients with unstable angina | double blind Follow-up duration: in hospital USA |
| van der Brand, 1991 | alteplase 100 mg in 3 h versus placebo | patients with angina at rest, despite bedrest and medical treatment | double blind Follow-up duration: hospital stay The Netherlands |
| charbonnier, 1992 | rt-PA 100 mg/90 minutes (10 mg bolus + 90 mg/90 minutes versus placebo | unstable angina pectoris | double blind |
| Ardissino, 1990 | recombinant tissue-type plasminogen activator (rt-PA) followed by heparin versus heparin alone | unstable angina refractory to conventional medical treatment | double blind Follow-up duration: in hospital Italy |
| TIMI 3B, 1995 | tissue-type plasminogen activator (t-PA) versus placebo | patients with unstable angina and non-Q wave myocardial infarction | Double blind Follow-up duration: 1 year |
| Topol, 1988 | intravenous tissue plasminogen activator (t-PA) versus placebo | patients with angina at rest and provocable ischemia (pacing induced) | open Follow-up duration: hospital stay USA |
| TIMI 3A, 1993 | 90-minute front-loaded infusion of t-PA (0.8 mg/kg i.v.; maximum, 80 mg) versus placebo | patients with unstable angina or non-Q wave myocardial infarction | double blind Follow-up duration: hospital stay USA, canada |
| ticagrelor versus clopidogrel | |||
| PLATO, 2009 NCT00391872 | ticagrelor 90mg twice daily versus clopidogrel 75mg once daily | patients with an acute coronary syndrome, with or without ST-segment elevation (onset of symptoms within the previous 24h). | double blind Follow-up duration: 1 y 43 countries |
| DISPERSE-2 (90mg), 2007 | ticagrelor 90 mg twice daily versus clopidogrel | patients with NSTE-ACS, treated with aspirin and standard therapy for ACS | double blind Follow-up duration: 12 weeks |
| ticlopidine versus control | |||
| STAI, 1990 | ticlopidine 250 mg b.i.d versus untreated control | patients with unstable angina <=48hrs from the pain onset | single blind Follow-up duration: 6m |
| Knudsen-A, 1985 | ticlopidine 500mg/d versus placebo | patients with AMI | double blind Follow-up duration: 3m |
| ticlopidine versus placebo | |||
| Florida UA, 0 | Ticlopidine 500mg/d versus | Follow-up duration: 14d | |
| trapidil versus placebo | |||
| Modena, 0 | trapidil versus | Follow-up duration: 6m | |
| triflusal versus aspirin | |||
| TIM, 2000 | triflusal 600 mg daily versus aspirine 300 mg daily | AMI within less than 24 h of symptom onsete | double blind Follow-up duration: 35 days Portugal, Spain, Italy |
| triflusal versus placebo | |||
| Plaza, 1993 | triflusal 300 mg three times daily versus placebo | patients with unstable angina | double blind Follow-up duration: 6m Spain |
| UFH versus control (on top of aspirin) | |||
| Holdright, 1994 | intravenous heparin plus oral aspirin (150 mg once daily) versus aspirin alone 150 mg/d | unstable angina | single blind Follow-up duration: hospital stay |
| RISC (heparin+aspirin vs ASP), 1990 | 5 days of intermittent intravenous heparin + oral aspirin 75 mg/day versus oral aspirin 75 mg/day | unstable angina or non-Q-wave myocardial infarction | open Follow-up duration: 90 days |
| Theroux (heparin+ASP vs ASP), 1988 | aspirin 325 mg/d + heparin 1000 UI/hr IV versus aspirin 325 mg/d | double blind Follow-up duration: 3-9 days | |
| UFH versus placebo | |||
| RISC (heparin vs PBO), 1990 | 5 days of intermittent intravenous heparin versus placebo | men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) | Follow-up duration: 1y (5,30 and 90 days) Sweden |
| Theroux (heparin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion) versus placebo | patients with acute unstable angina pectoris | double blind Follow-up duration: 3-9 days |
| UFH versus placebo (on top of aspirin) | |||
| Gurfinkel (UFH+aspririn vs aspirin), 1995 | aspirin plus UFH 5000 IU iv then 400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time versus aspirin 200 mg/day | patients greater than 21 years with ustable angina within 24 hours of randomizationcatio | double blind Follow-up duration: 5-7 days |
| UFH + aspirin versus placebo | |||
| RISC (ASP+ heparin vs PBO), 1990 | oral apsirin 75mg/d + intermittent IV heparin 10000UI/d followed by 7500 UI 6-hourly for 4 days versus placebo | men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) | Follow-up duration: 1y (5,30 and 90 days) Sweden |
| Theroux (heparin+aspirin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion)+ aspirin (325 mg twice daily) versus aspirin (325 mg twice daily) | double blind Follow-up duration: 3-9 days | |
| UFH, warfarin versus aspirin | |||
| Cohen (ATACS pilot) (heparin vs asp), 1990 | heparin followed by warfarin (without aspirin) versus aspirin 325 mg/day | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening | open Follow-up duration: 12 weeks |
| UFH, warfarin versus control (on top of aspirin) | |||
| ATACS (Cohen), 1994 | aspirin 162.5 mg daily plus heparin (activated partial thromboplastin time, two times control) followed by aspirin 162.5 mg daily plus warfarin (international normalized ratio, 2 to 3) for 12 weeks. versus aspirin alone (162.5 mg daily) for 12 weeks. | patients with unstable rest angina or non-Q-wave myocardial infarction with last episode of pain within 48 hours of randomization and who were nonprior aspirin users | single blind Follow-up duration: 12 weeks |
| Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 | aspirin (80 mg/day) plus heparin and then warfarin versus aspirin (325 mg/day) | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening. | open Follow-up duration: 12 weeks |
| vorapaxar versus placebo (on top standard therapy) | |||
| TRACER, 2011 NCT00527943 | vorapaxar (SCH 530348) oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
versus Placebo (added to the existing standard of care (eg, aspirin, clopidogrel) | patients with acute coronary syndrome | double-blind |
| warfarin versus aspirin | |||
| ATACS (pilot study) warfarin vs aspirin, 1990 | heparin/warfarin target INR 3-4 versus aspirin 325 mg daily | UA, NSTEMI | open Follow-up duration: 3 months |
| warfarin versus control (on top of aspirin) | |||
| ATACS (pilot study) (warfarin vs control), 1990 | heparin/warfarin target INR 3-4.5 + aspirin versus aspirin alone | UA, NSTEMI | open Follow-up duration: 3 months |
| ATACS, 1994 | heparin/warfarin (INR median 2.3) + aspirin versus aspirin | UA, NSTEMI | open Follow-up duration: 3 months |
| CARS, 1997 | warfarin (INR mean 1.5) (3 mg warfarin or 1 mg warfarin with 80 mg aspirin) versus aspirin 160 mg/d | AMI | Follow-up duration: 14 months |
| OASIS Pilot (phase 1), 1998 | warfarin 3mg/d for 6 months (INR mean 1.5) versus control | UA, NSTEMI | open Follow-up duration: 6 months |
| OASIS Pilot (phase 2), 1998 | warfarin adjusted dose (INR mean 2.3) for 3 months versus standard treatment | UA, NSTEMI | open Follow-up duration: 3 months |
| OASIS-2 Warfarin Substudy, 2001 | warfarin target INR 2–2.5 for 5 months +aspirin versus control | UA | open Follow-up duration: 5 months |
| APRICOT-2, 2002 | moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin | STEMI | Follow-up duration: 3 months |
| CHAMP, 2002 | warfarin (INR median 1.8) versus | AMI | Follow-up duration: 2.7 years |
| WARIS, 2002 | warfarin (INR 2.2 (mean) versus | AMI | Follow-up duration: 4 years |
| LoWASA, 2004 | warfarin (prothrombin complex activity mean 95.5) versus | AMI | Follow-up duration: 5 years |
| Zibaeenezhad, 2004 | Warfarin target INR 2–3 versus | AMI | Follow-up duration: 1 year |
| warfarin versus placebo (on top of aspirin) | |||
| Williams, 1997 | warfarin target INR 2–2.5 +aspirin versus placebo +aspirin | UA, AMI | double blind Follow-up duration: 2.5 months |
| Huyhn, 2001 | warfarin adjusted dose for INR 2–2.5 +aspirin versus placebo +aspirin | UA, NSTEMI with prior CABG | double blind Follow-up duration: 1 year |
| ximelagatran versus placebo | |||
| ESTEEM, 2003 | oral ximelagatran at doses of
24 mg, 36 mg, 48 mg, or 60 mg twice daily versus placebo | patients who had had recent ST-elevation or non-STelevation myocardial infarction | double-blind Follow-up duration: 6 months |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
